MEDYSAPIENS
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
MEDYSAPIENS - overview
Established
2016
Location
Seoul, -, South Korea
Primary Industry
Biotechnology
About
Based in Seoul, South Korea, and founded in 2016, MedySapiens combines technologies like bioinformatics, and artificial intelligence (AI) to develop a solution for the early diagnosis of rare genetic diseases in newborns. In March 2022, MEDYSAPIENS raised KRW 7 billion in a Series A funding from Korea Venture Investment Corporation, L&S Venture Capital, Vision Creator, and an unspecified investor. As of March 2022, Sanggoo Kang is the CEO of the company. The product line of MedySapiens includes A.
I. ssist Medy4skin, NEOseq Action panel, and A. I. ssist MedyCVi.
A. I. ssist Medy4skin is an artificial intelligence system with deep learning technology that helps in evaluating the skin on 4 items like oil/moisture, wrinkles, pores, and tones. NEOseq Action panel provides therapeutics and diagnosis guidance on targeted genetic testing on diseases from actionable genes.
A. I. ssist MedyCVi is a cloud solution that provides NEOseq_Action panel for neonatal intensive care unit (NICU), allowing healthcare professionals to get better accuracy.
Current Investors
L&S Venture Capital, Vision Creator, Korea Venture Investment Corporation
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Molecular Science, Genetics & Gene Therapy, Healthcare IT, Medical Software
Website
www.medysapiens.com
Verticals
Artificial Intelligence, HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.